Application of compound probiotic agent in preparing products for treating ulcerative colitis

Abstract

The invention provides application of a compound probiotic agent in preparing products for treating ulcerative colitis. The compound probiotic agent contains four probiotic lactic acid strains, namelylactobacillus casei Zhang, bifidobacterium zoonosus V9, lactobacillus plantarum P-8 and lactobacillus plantarum C2, and the probiotics all have good acid resistance, artificial gastrointestinal fluidtolerance and bile salt tolerance, and do not carry drug-resistant plasmids. The four probiotic strains are high in safety. The compound probiotic agent further contains prebiotics which can synergize with the probiotics, and then the probiotic function of the probiotics is ensured. Accordingly, the compound probiotic agent has remarkable curative effect on the ulcerative colitis, the probiotic function of an intestinal flora can be adjusted so as to make the intestinal flora healthy, and by taking the compound probiotic agent as an adjuvant drug for treating the ulcerative colitis, the compound probiotic agent has the advantages of being simple in treatment, high in remission rate, free of toxic or side effects and the like.

Description

technical field [0001] The application belongs to the field of biological preparations, and in particular relates to the use of a compound probiotic agent for preparing products for treating ulcerative colitis. Background technique [0002] Ulcerative colitis (Ulcerative colitis, UC) is a chronic non-specific intestinal inflammatory disease with unknown etiology and pathogenesis, and is a subtype of inflammatory bowel disease (Inflammatory bowel disease, IBD). The rate is increasing year by year globally. Ulcerative colitis mainly manifests as colonic mucosal lesions, mostly ulcers, and the lesions mostly occur in the rectum and sigmoid colon, and even involve the entire colon. Currently, UC is believed to be caused by multiple factors such as genetic factors, immune dysfunction, intestinal barrier dysfunction, and changes in intestinal microecology. [0003] The traditional method of treating ulcerative colitis is to take antibiotics orally, and antibiotics have low selec...

AI Technical Summary

Problems solved by technology

[0003] The traditional method of treating ulcerative colitis is to take antibiotics orally, and antibiotics have low selectivity to the intestinal flora. When the pathogenic bacteria in the intestinal tract are killed, the probiotics in the intestinal tract will also be destroyed in large quantities. Kill, and then disrupt the balance of the intestinal flora of patients, resulting in a lower rate of remission of ulcerative colitis

Images